ДЕННИ Уилльям С. (US),ДЖЕКСОН Маргарет (US),СОННЕНБЕРГ Габриель (US)
申请号：
RU2014146109
公开号：
RU2014146109A
申请日:
2013.05.21
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating sleep disorders in a patient comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of (R) -2- (2-methylimidazo [2,1-b] thiazol-6-yl) -1- (2 - (5- (6-methyl-pyrimidin-4-yl) -2,3-dihydro-1H-inden-1-yl) -2,7-diazaspiro [3.5] nonane-7-yl) ethanone or a pharmaceutically acceptable salt thereof. 2. A method according to Claim. 1, wherein the sleep disorder is primary bessonnitsa.3. A method according to Claim. 1, wherein the sleep disorder is excessive daytime sleepiness vremya.4. A method according to claim. 3, where the patient has Villi.5-Prader syndrome. A method according to Claim. 1, wherein the sleep disorder is syndrome edy.6 night. A method of treating sleep disorders in a patient comprising the step of administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of (R) -2- (2-methylimidazo [2,1-b] thiazol-6-yl) -1- (2- (5- (6-methyl-pyrimidin-4-yl) -2,3-dihydro-1H-inden-1-yl) -2,7-diazaspiro [3.5] nonane-7-yl) ethanone or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier, diluent or ekstsipient.7. A method according to claim. 6, wherein the sleep disorder is primary bessonnitsa.8. A method according to claim. 6, wherein the sleep disorder is excessive daytime sleepiness vremya.9. A method according to claim. 8, where the patient has Villi.10-Prader syndrome. A method according to claim. 6, wherein the sleep disorder is syndrome edy.11 night. A method according to any one of claims 1-10, wherein (R) -2- (2-methylimidazo [2,1-b] thiazol-6-yl) -1- (2- (5- (6-methyl-pyrimidin-4-yl) -2,3 dihydro-1H-inden-1-yl) -2,7-diazaspiro [3.5] nonane-7-yl) ethanone or a pharmaceutically acceptable salt thereof is administered in combination with another pharmacologically active agent.1. Способ лечения расстройства сна у пациента, включающий стадию введения пациенту, нуждающемуся в таком лечении,
